Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia

被引:4
|
作者
Maiguma, T. [1 ]
Hayashi, Y. [2 ]
Ueshima, S. [2 ]
Kaji, H. [1 ]
Egawa, T. [1 ]
Chayama, K. [4 ]
Morishima, T. [4 ]
Kitamura, Y. [3 ]
Sendo, T. [2 ]
Gomita, Y. [1 ]
Teshima, D. [1 ]
机构
[1] Shujitsu Univ, Dept Clin Pharm, Sch Pharm, Okayama 7038516, Japan
[2] Okayama Univ Hosp, Dept Hosp Pharm, Okayama, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharmaceut Sci, Okayama, Japan
[4] Okayama Univ Hosp, Dept Pediat, Okayama, Japan
关键词
high-dose methotrexate chemotherapy; pediatric acute lymphoblastic leukemia; oral mucositis; human epidermal keratinocytes; cell viability; pharmacokinetic parameters;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Oral mucositis is a major toxicity in the high-dose methotrexate (HD-MTX) treatment for children with acute lymphoblastic leukemia (ALL). The first aim Of this Study was to evaluate the relationship between the MTX serum concentration and Occurrence of oral mucositis in pediatric ALL patients. The second aim was to clarify the relationship between MTX exposure and epidermal keratinocyte cell injury using an in vitro study. Methods: 49 patients were treated according to the Japan Association of Childhood Leukemia Study (JACLS) ALL-HR02 protocol. This protocol involves HD-MTX treatment (3 g/m(2) for 24-h i.v. infusion). The MTX serum concentrations were measured by a fluorescence polarization immunoassay. The relationship between oral mucositis and MTX serum concentrations 48 and 72 h after administration was determined. The cell toxicity or MTX for epidermal keratinocytes was analyzed by using a cell viability assay (WST-1 assay). In addition, pharmacokinetic evaluation for clearance, AUC extrapolated from 48 h to infinity (AUC(48h-infinity)) and elimination half-life 01,1210 were done using the 1-compartmental models. Results: Oral mucositis occurred in 24 patients (49.0%), in whom 20 patients (83.3% in oral mucositis group) showed WHO severity Grade 1 or 2. Only 4 patients (16.7% in oral mucositis group) showed Grade 3 severity. 22 patients (44.9%) had oral mucositis in the group With a concentration under 10(-6) M 48 h after MTX administration. There was no significant deference among the cell viabilities in the Concentrations of 10(-6) M, 10(-5) M and 10(-4) M 48 h after the MTX exposure. However, the cell viability obtained 24 h after the MTX exposure was significantly different from the respective cell viability 48, 72 and 96 h after the MTX exposure. In the group with oral mucositis, the clearance decreased significantly (p = 0.042), and the t(1/2 beta) (p = 0.025) and AUC(48h-infinity), (P = 0.025) increased significantly compared with the non-symptom group. Conclusions: It seems that there is no significant relationship between the serum MTX concentration and oral mucositis. This in vitro Study has demonstrated that the cell injury was related to the duration of MTX exposure rather than a high MTX concentration.
引用
收藏
页码:584 / 590
页数:7
相关论文
共 50 条
  • [41] Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
    Barakat, Shaimaa
    Assem, Hala
    Salama, Mostafa
    Mikhael, Neveen
    El Chazli, Yasmine
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2022, 34 (01)
  • [42] Myelotoxicity Following High-Dose Methotrexate in Children with Down Syndrome and Acute Lymphoblastic Leukemia
    Bohnstedt, C.
    Levinsen, M.
    Rosthoj, S.
    Zeller, B.
    Taskinen, M.
    Hafsteinsdottir, S.
    Bjorgvinsdottir, H.
    Heymann, M.
    Schmiegelow, K.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S104 - S104
  • [43] Repeated Episodes of Leukoencephalopathy after High-dose Methotrexate in a Child with Acute Lymphoblastic Leukemia
    Tsao, Teng-Fu
    Chao, Yu-Hua
    INDIAN PEDIATRICS, 2017, 54 (02) : 159 - 159
  • [44] Dose-individualization Efficiently Maintains Sufficient Exposure to Methotrexate without Additional Toxicity in High-dose Methotrexate Regimens for Pediatric Acute Lymphoblastic Leukemia
    Shen, Ya-qing
    Wang, Zhu-jun
    Wu, Xiao-yan
    Li, Kun
    Wang, Zhong-jian
    Xu, Wen-fu
    Zhou, Fen
    Jin, Run-ming
    CURRENT MEDICAL SCIENCE, 2022, 42 (04) : 769 - 777
  • [45] Dose-individualization Efficiently Maintains Sufficient Exposure to Methotrexate without Additional Toxicity in High-dose Methotrexate Regimens for Pediatric Acute Lymphoblastic Leukemia
    Ya-qing Shen
    Zhu-jun Wang
    Xiao-yan Wu
    Kun Li
    Zhong-jian Wang
    Wen-fu Xu
    Fen Zhou
    Run-ming Jin
    Current Medical Science, 2022, 42 : 769 - 777
  • [46] THE RESEARCH OF THE RELATIONSHIP BETWEEN RFC1A80G GENETIC POLYMORPHISMS AND HIGH-DOSE METHOTREXATE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
    Hong, L.
    Hui, J.
    Qin, L.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 55 - 55
  • [47] Efficacy and association analysis of high-dose methotrexate in the treatment of children with acute lymphoblastic leukemia
    Gong, Fangwei
    Meng, Qingjun
    Liu, Chengjuan
    Zhao, Yeqi
    ONCOLOGY LETTERS, 2019, 17 (05) : 4423 - 4428
  • [48] Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
    Shaimaa Barakat
    Hala Assem
    Mostafa Salama
    Neveen Mikhael
    Yasmine El Chazli
    Journal of the Egyptian National Cancer Institute, 34
  • [49] Severe nephrotoxicity during high-dose methotrexate administration in an adolescent with acute lymphoblastic leukemia
    Queizan, Lucia
    Peruzzo, Luisina
    Ibanez, Juan
    Felice, Maria S.
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2024,
  • [50] Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia
    Rubnitz, JE
    Relling, MV
    Harrison, PL
    Sandlund, JT
    Ribeiro, RC
    Rivera, GK
    Thompson, SJ
    Evans, WE
    Pui, CH
    LEUKEMIA, 1998, 12 (08) : 1176 - 1181